Our results demonstrated that AHR was significantly decreased in PB or BM of ND CML patients (0.2647 ± 0.3103 or 0.1653 ± 0.2083) compared with CP patients (0.8243 ± 0.4582 or 0.5892 ± 0.4755; *P = 0.000 or *P = 0.000) and healthy controls (0.5560 ± 0.2245 or 0.4368 ± 0.4194; *P = 0.017 or *P = 0.024). The gene discussed is AHR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.